Pharmacosmos hires Chris Olsen DVM

August 29, 2016

Pharmacosmos has hired Chris Olsen DVM, as sales and technical support for Uniferon® 200 mg/mL (Iron(III) Dextran) throughout the United States.

Based near Des Moines, IA, Dr. Olsen will help veterinarians and large commercial swine operations with the prevention and treatment of sub-clinical and full-scale iron deficiency anemia in baby pigs through injectable supplementation of Uniferon® 200 mg/mL. Duties will include further deployment and training for the Uniferon® Farm Anemia Certification and Training (F.A.C.T) program, whereby production managers and swine veterinarians have access to convenient pen-side diagnostic tools and knowledge that eliminate guesswork commonly associated with detection of iron deficiency anemia.

Chris will also serve as the primary liaison to university swine programs, state and national swine associations, spearhead field trials and research, and present relevant research and updates at major swine events.

Olsen is a recent graduate of the College of Veterinary Medicine, Iowa State University, in Ames, IA and already has a wide breadth of experience designing and conducting research trials.

About Injectable Iron

Baby pigs are very susceptible to iron deficiency anemia. Therefore, iron deficiency anemia in litters of baby pigs poses a risk to both animal health, welfare, and productivity. An injection of iron shortly after farrowing is an effective and is a globally established "best practices method" utilized to prevent iron deficiency anemia in baby pigs.

About Uniferon 200

Uniferon 200 is a modern and much improved iron hydrogenated dextran, based upon a very low impurity profile formulation, whereby this source of injectable iron for baby pigs has been approved by numerous healthcare authorities for global use.

Pharmacosmos manufactures iron dextran of high quality and unique purity, which is distributed to human and animal drug customers worldwide. Uniferon 200 is the only injectable iron brand for baby pigs approved by healthcare authorities in the EU, in the U.S. and in Asia.

About Pharmacosmos

Pharmacosmos Inc, located in Watchung, NJ as a fully owned subsidiary of Pharmacosmos A/S. is dedicated to the sales of veterinary pharmaceuticals for the treatment and prevention of iron deficiency Anemia, including Uniferon 200.

Headquartered in Holbaek, Denmark, Pharmacosmos A/S is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, the Pharmacosmos A/S ongoing R&D program focuses on improving the lives of patients with sub-clinical and full-scale iron deficiency anemia. More than 1 billion people live with iron deficiency anemia and it is the leading cause of death for an estimated 180,000 people world-wide every year. This makes sub-clinical and full-scale iron deficiency anemia one of the largest global health challenges of the current time.

Pharmacosmos A/S has subsidiaries in the US, China, Nordics, Germany, UK and Ireland, and its products are marketed in more than 80 countries around the world. The Pharmacosmos A/S manufacturing facilities located in Denmark have supported global healthcare authority approvals, among others, by the Danish Medicines Agency and the U.S. FDA.